Ensitrelvir Fumarate Intermediates 04
1 Inquiries
2647530-73-0
Pharmaceutical Grade
99%
shanghai
Alicorn
25kg/Cardboard Drum
Yes
2023-09-15
Betahistine Mesylate,Azilsartan Medoxomil Potassium,Pimavanserin Tartrate,Iguratimod
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceA clinical candidate for treating COVID-19, Ensitrelvir (a nonproprietary name for S-217622), which was discovered through a research collaboration between Shionogi & Co., Ltd. and Hokkaido university, as the first nonpeptidic, noncovalent CLpro inhibitor. Ensitrelvir exhibited significant potent antiviral activity and high bioavailability arising from a favorable drug metabolism and pharmacokinetic (DMPK) profile as a once-daily oral medicine to treat COVID-19.
Ensetivir is a light brown or off-white powder and is an orally active, non-covalent, non-peptide SARS-CoV-2 3CL protease inhibitor.Basic Info-
Product Name:
Ensitrelvir
Other Name:1,3,5-Triazine-2,4(1H,3H)-dione, 6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-, (6E)-;(E)-6-((6-chloro-2-methyl-2H-indazol-5-yl)imino)-3-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1-(2,4,5-trifluorobenzyl)-1,3,5-triazinane-2,4-dione;Ensitrelvir (S-217622);WIDELY Ensitrelvir;S-217622-002;Ensitrelvir/1,3,5-Triazine-2,4(1H,3H)-dione, 6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-, (6E)-;intrapulmonary replication,Virus Protease,COVID-19,S217622,oral,SARS-CoV,Ensitrelvir,SARS coronavirus,S-217622,variant,S 217622,Inhibitor,inhibit;S-217622 (Ensitrelvir)
CAS No.:2647530-73-0
Molecular Formula:C22H17ClF3N9O2
InChIKeys:QMPBBNUOBOFBFS-UHFFFAOYSA-N
Molecular Weight:531.88
Color/Form:White to light yellow
Categories:
Characteristics-
Density:
1.65±0.1 g/cm3(Predicted)
Boiling Point:696.2±65.0 °C(Predicted)
PKA:5.19±0.20(Predicted)
Critical Temperature & Pressure:2-8°C
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Betahistine Mesylate,Azilsartan Medoxomil Potassium,Pimavanserin Tartrate,Iguratimod
-
Location:
Building 4, Juanhu Int. Sci & Innovation Park, No. 500, Shuiyueting East Road, Xishi Street, Haining, Jiaxing, Zhejiang
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
20 days
-
Total Annual Revenue:
$25 million-$50 million
-
Total Employees:
201-300
-
Year of Establishment:
2021
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted
India
NELFINAVIR
25.00 G Feb 25, 2026 Post an enquiry for this product
More from this Seller
-
-
-
Netarsudil Mesylate api
Pharmaceutical Grade / 99%
-
-
-
-
BempedoicAcid API 01
Pharmaceutical Grade / 99%
-
-
-
-
Dronedarone Hydrochloride API 02
Pharmaceutical Grade / 99%
-
-
-
-
PF-06651600/ritlecitinib api
Pharmaceutical Grade / 99%
-
-
-
-
Tofacitinib API 540737-29-9
Pharmaceutical Grade / 99%
-
-
-
-
Cenobamate
Pharmaceutical Grade / 99%
-